Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)

Thomas Powles, Mark Kockx, Alejo Rodriguez-Vida, Ignacio Duran, Simon J. Crabb, Michiel S. van der Heijden, Bernadett Szabados, Albert Font Pous, Gwenaelle Gravis, Urbano Anido Herranz, Andrew Protheroe, Alain Ravaud, Denis Maillet, Maria Jose Mendez, Cristina Suarez, Mark Linch, Aaron Prendergast, Pieter-Jan van Dam, Diana Stanoeva, Sofie DaelemansSanjeev Mariathasan, Joy S. Tea, Kelly Mousa, Romain Banchereau, Daniel Castellano

Research output: Contribution to journalComment/Letter to the editorAcademic

1 Citation (Scopus)

Abstract

In the version of this article initially published, the labels in the key to Fig. 1f (red bars, Down in responders; blue bars, Up in responders) were incorrect. The correct labels are as follows: red bars, Up in responders; blue bars, Down in responders. Also, the histopathology images in Fig. 2a were incorrect. The correct images are now provided. The errors have been corrected in the HTML and PDF versions of the article.

Original languageEnglish
Pages (from-to)983
Number of pages1
JournalNature medicine
Volume26
Issue number6
Early online date2020
DOIs
Publication statusPublished - 1 Jun 2020

Cite this